LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice

Cancer Chemotherapy and Pharmacology

Volumn 53, Issue 2, 2004, Pages 133-140

  Keyes, Kristan A ^a,c   Mann, Larry ^a   Sherman, Michael ^a   Galbreath, Elizabeth ^a   Schirtzinger, Linda ^a   Ballard, Darryl ^a   Chen, Yun Fei ^a   Iversen, Philip ^a   Teicher, Beverly A ^a,b  

^a ELI LILLY AND COMPANY   (United States)

^b GENZYME CORPORATION   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Antiangiogenesis; Caki 1 renal cell cancer; LY317615; Protein kinase C; SW2 SCLC; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; ENZASTAURIN; PROTEIN KINASE C BETA INHIBITOR; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CANCER MODEL; CONTROLLED STUDY; DISEASE MARKER; DRUG INHIBITION; DRUG RESPONSE; DRUG WITHDRAWAL; EXPERIMENTAL MODEL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS INHIBITION; SPECIES COMPARISON; TUMOR BLOOD FLOW; TUMOR GROWTH; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; BODY WEIGHT; CELL LINE, TUMOR; ENZYME INHIBITORS; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE C; REGIONAL BLOOD FLOW; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0442329299     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0713-x     Document Type: Article

References (46)

1. Jung Y, Ahmad S, Akagi Y, Takahashi Y, Liu W, Reinmuth N, Shaheen R, Fan F, Ellis L (2000) Role of the tumor microenvironment in mediating response to anti-angiogenic therapy. Cancer Metastasis Rev 19:147-157
2. Oehler MK, Caffier H (2000) Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Anticancer Res 20:5109-5112
3. Salven P, Orpana A, Teerenhovi L, Joensuu H (2000) Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 96:3712-3718
4. Gasparini G (2001) Clinical significance of determination of surrogate markers for angiogenesis in breast cancer. Crit Rev Oncol Hematol 37:97-114
5. Sheen-Chen S, Chen H, Sheen C, Eng H, Chen W (2001) Serum levels of transforming growth factor β1 in patients with breast cancer. Arch Surg 136:937-940
6. Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B (2000) Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 163:343-347
7. Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, Henriksson R (2000) Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant chemotherapy. J Clin Oncol 18:1423-1431
8. Foekens J, Peters H, Grebenchtchikov M, Look M, Meijer-Van Gelder M, Geurts-Moespot A, van der Kwast T, Sweep C, Klijn G (2001) High tumor levels of VEGF predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61:5407-5414
9. Chin K, Greenman J, Gardiner E, Kumar H, Topping K, Monson J (2000) Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br J Cancer 11:1425-1431
10. Broll R, Erdmann H, Duchrow M, Oevermann E, Schwandner O, Merkert U, Bruch H, Windhovel U (2001) Vascular endothelial growth factor (VEGF) - a valuable serum tumor marker in patients with colorectal cancer? Eur J Surg Oncol 27:37-42
11. Werther K, Christensen I, Brunner N, Nielsen H, and the Danish RANX05 Colorectal Cancer Study Group (2000) Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. Eur J Surg Oncol 26:657-662
12. Takeda A, Shimada H, Imaseki H, Okazumi S, Natsume T, Suzuki T, Ochiai T (2000) Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients: correlation with clinicopathological factors and tumor markers. Oncol Rep 7:333-338
13. Slaton J, Inoue K, Perrotte P, El-Naggar A, Swanson D, Fidler I, Dinney C (2001) Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 158:735-743
14. Han H, Silverman J, Santucci T, Macherey R, dAmato T, Tung M, Weyant R, Landreneau R (2001) Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 8:72-79
15. Baillie R, Carlile J, Pendleton N, Schor A (2001) Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer. J Clin Pathol 54:116-120
16. Kido Y (2001) Vascular endothelial growth factor (VEGF) serum concentration changes during chemotherapy in patients with lung cancer. Kurume Med J 48:43-47
17. Abendstein B, Daxenbichler G, Windbichler G, Zeimet A, Geurts A, Sweep F, Marth C (2000) Predictive value of uPA, PAI-1, HER-2, and VEGF in the serum of ovarian cancer patients. Anticancer Res 20:569-572
18. Hyodo I, Doi T, Endo H, Hosokawa Y, Nishikawa Y, Tanimizu M, Jinno K, Kotani Y (1998) Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 34:2041-2045
19. Takiuchi H, Hirata I, Kawabe S, Egashira Y, Katsu K (2000) Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma. Oncol Rep 7:841-846
20. Pal S, Claffey KP, Cohen H, Mukhopadhay D (1998) Activation of Sp-1 mediated vascular permeability growth factor transcription requires specific interaction with protein kinase C zeta. J Biol Chem 273:26277-26280
21. Pal S, Datta K, Khosravi-Far R, Mukhopadhyay D (2001) Role of Protein kinase C zeta ras-mediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression. J Biol Chem 276:2395-2403
22. Shih S, Mullen A, Abrams K, Mukhopadhyay D, Claffey K (1999) Role of protein kinase C isoforms in phorbol ester-induced vascular endothelial growth factor expression in human glioblastoma cells. J Biol Chem 274:15407-15414
23. Chabannes E, Fauconnet S, Bernardini S, Wallerand H, Adessi G, Bittard H (2001) Protein kinase C signaling pathway is involved in the regulation of vascular endothelial growth factor expression in human bladder transitional cancer. Cell Signal 13:585-591
24. Aiello L, Bursell S, Clemont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla T, Ways K, Jirousek M, Smith L, King G (1997) Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 46:1473-1480
25. Danis R, Bingaman D, Jirousek M, Yang Y (1998) Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Ophthalmol Vis Sci 39:171-179
26. Ishii H, Jirousek M, Koya D, Takagi C, Xia P, Clermont A, Bursell S, Kern T, Ballas L, Heath W, Stramm L, Feener E, King G (1996) Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor (see comments). Science 272:728-731
27. Jirousek M, Gillig J, Gonzalez C, Heath W, McDonald J, Neal D, Rito C, Singh U, Stramm L, Melikian-Badalian A, Baevsky M, Ballas L, Hall S, Winneroski L, Faul M (1996) (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiaza-cyclohexadecene- 1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem 39:2664-2671
28. Teicher BA, Alvarez E, Menon K, Esterman MA, Considine E, Shih C, Faul MM (2002) Antiangiogenic effects of a protein kinase C beta-selective small molecule. Cancer Chemother Pharmacol 49:69-77
29. Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul MM (2001) Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human HT-29 colon carcinoma and human Caki-1 renal cell carcinoma xenografts. Anticancer Res 21:3175-3184
30. Teicher BA, Menon K, Alvarrez E, Galbreath E, Shih C, Faul MM (2001) Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in murine Lewis lung carcinoma and human Calu-6 non-small cell lung carcinoma xenografts. Cancer Chemother Pharmacol 48:473-480
31. Teicher BA, Menon K, Alvarez E, Liu P, Shih C, Faul MM (2001) Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human hepatocellular and gastric cancer xenografts. In Vivo 15:185-193
32. Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul MM (2001) Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human T98G glioblastoma multiforme xenografts. Clin Cancer Res 7:634-640
33. Thornton DE, Keyes K, Mann L, Marder P, Cox K, Treadway P, Sherman M, Galbreath E, Menon K, Iversen P, Chen Y-F, Teicher BA (2002) Determination of cancer growth factor biomarkers in plasma from mice bearing subcutaneous human tumor xenografts using Luminex Multiplex technology. Proc Am Assoc Cancer Res 43:897
34. Keyes K, Cox K, Treadway P, Mann L, Shih C, Faul MM, Teicher BA (2002) An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy. Cancer Res 62:5597-5602
35. Keyes KA, Mann L, Cox K, Treadway P, Iversen P, Chen Y-F, Teicher BA (2003) Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex multiplex technology. Cancer Chemother Pharmacol 51:321-327
36. Herbst RS, Thornton DE, Kies MS, Sinha V, Flanagan S, Cassidy CA, Carducci MA (2002) Phase 1 study of LY317615, a protein kinase Cβ inhibitor (abstract 326). Proceedings ASCO Annual Meeting
37. Keyes KA, Mann L, Cox K, Treadway P, Mann L, Iversen P, Chen Y, Teicher BA (2002) Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology (abstract 4451). Proceedings ASCO Annual Meeting
38. Kakeji Y, Maehara Y, Ikebe M, Teicher BA (1997) Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-beta levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma. Int J Radiat Oncol Biol Phys 37:1115-1123
39. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1:27-23
40. Teicher BA (ed) (1999) Antiangiogenic agents in cancer therapy. Humana Press, New Jersey
41. Myoung H, Hong S, Kim Y, Hong S, Kim M (2001) Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma. Cancer Lett 163:191-200
42. Guba M, Cernaianu G, Koehl G, Geissler E, Jauch K, Anthuber M, Falk W, Steinbauer A (2001) Primary tumor promoters dormancy of solitary tumor cells before inhibiting angiogenesis. Cancer Res 61:5575-5579
43. Kim K, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362:841-844
44. Asano M, Yukita A, Suzuki H (1999) Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Jpn J Cancer Res 90:93-100
45. Monsky WL, Carreira CM, Tsuzuki Y, Gohongi T, Fukumura D, Jain RK (2002) Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin Cancer Res 8:1008-1013
46. Fong T, Shawver L, Tang C, App H, Powell T, Kim Y, Schreck R, Wang X, Risau W, Ullrich A, Hirth K, McMahon G (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99-106